• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Resources

Breakthrough COVID-19 Following Vaccination: What are the Risk Factors?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Antonelli et al. (Lancet Infectious Diseases, 2021) identified risk factors for post-vaccination “breakthrough” SARS-CoV-2 infection and characteristics of post-vaccination illness 

METHODS:

  • Prospective, community-based, nest, case-control study 
  • Population 
    • Adult users of the COVID Symptom Study app in the UK  
    • No prior positive COVID-19 test 
  • Exposures 
    • Group 1 
      • Vaccinated, with a COVID-19 test at least 14 days after their first vaccination (but before their second) 
    • Group 2 
      • Vaccinated, with a test at least 7 days after their second vaccination 
    • Group 3 
      • Group 1, but users who used the app for at least 14 consecutive days after testing positive 
    • Group 4 
      • Group 2, but users who used the app for at least 14 consecutive days after testing positive 
  • Study design 
    • Cases: Those with positive tests  
    • Controls: Those with negative tests 
    • 1:1 matching 
      • The date of the post-vaccination test 
      • Health-care worker status 
      • Sex 
      • BMI (for group 3 and 4) 
      • Age (for group 3 and 4) 
    • Univariate logistic regression models (adjusted for age, BMI, and sex) were used to analyze the associations of outcomes and vaccination status 
  • Primary outcomes 
    • Individual symptoms 
    • Overall disease duration 
    • Disease severity 

RESULTS:

Risk factor analysis 

  • 1,240,009 reported a first vaccine dose | 971,504 reported a second dose 
    • Positive COVID-19 tests after first dose: 0.5% 
    • Positive COVID-19 tests after second dose: 0.2% 
  • Risk factors associated with breakthrough infection following the first dose 
    • Frailty in older adults (≥60 years) 
      • Odds ratio 1.93 (95% CI, 1.50 to 2.48); P<0.0001 
    • Living in highly deprived areas 
      • OR 1.11 (95% CI, 1.01 to 1.23); P=0.039 
  • BMI: Individuals without obesity (BMI <30 kg/m2) had lower odds of infection following their first vaccine dose 
    • OR 0.84 (95% CI, 0.75 to 0.94); P=0.0030 

Disease profile analysis 

  • Vaccination (vs no vaccination) was associated with reduced odds of 
    • Hospitalization 
    • Having >5 symptoms in the first week of illness following the first or second dose 
    • Long-duration (≥28 days) symptoms following the second dose 
  • Almost all symptoms were reported less frequently in infected vaccinated individuals than in infected unvaccinated individuals 
  • Vaccinated participants were more likely to be completely asymptomatic, especially if they were ≥60 years  

CONCLUSION:

  • Breakthrough infections remain rare in vaccinated individuals, but frail older adults, individuals living in deprived areas and those with obesity are at higher risk  
    • The authors suggest that these higher risk individuals might represent populations best suited for “booster” doses 
  • The authors state

We found that the odds of having symptoms for 28 days or more after post-vaccination infection were approximately halved by having two vaccine doses 

This result suggests that the risk of long COVID is reduced in individuals who have received double vaccination, when additionally considering the already documented reduced risk of infection overall 

Lancet Infectious Diseases, 2021

Learn More – Primary Sources

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study 

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Resources Posts
Next >

Related ObG Topics:

How does Vaccination Impact Viral Load and Duration of Illness in Those with Breakthrough SARS-CoV-2 Infection?
The Value of Vaccination for Those Previously Infected with SARS-CoV-2
mRNA-Based COVID-19 Vaccines Induce Robust, Persistent Immune Responses in Humans

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site